ALK and hepatosplenic T-cell lymphoma: The final cohort included 174 patients with PTCL-NOS, 144 angoimmunoblastic T-cell lymphoma (AITL), 74 ALK+ ALCL, 103 ALK-ALCL, 54 ENKL, 23 hepatosplenic T-cell lymphoma (HSTL), 16 EATL, and 12 subcutaneous panniculitis-like T-cell lymphoma (SPTL).